Investigational drug · Phase 2
SX-682
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
14
Any phase or sponsor naming "SX-682"
First trial start
2024
Nov 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SX-682", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SX-682" as an intervention, largest first.
Syntrix Biosystems, Inc.Industry
NCT04245397 · 151 participants (planned) · Start Jun 30, 2020 · Primary completion Mar 2028
Drug: SX-682; Decitabine · For: Myelodysplastic Syndromes
Sites: Jacksonville, Florida; Miami, Florida; Orlando, Florida · 7 sites in all
National Cancer Institute (NCI)NIH
NCT07667400 · 120 participants (planned) · Start Nov 24, 2026 · Primary completion Oct 1, 2036
Drug: SX-682; DTX · For: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Paranasal Sinus Neoplasms and 9 more
Sites: Bethesda, Maryland
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT07002320 · 78 participants (planned) · Start Apr 28, 2025 · Primary completion Oct 2029
Drug: SX-682; Apalutamide · For: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Sites: Bellinzona, Switzerland; Belfast, United Kingdom; Cambridge, United Kingdom · 4 sites in all
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabActive, not recruiting
Syntrix Biosystems, Inc.Industry
NCT03161431 · 77 participants (planned) · Start Jun 12, 2019 · Primary completion Jul 31, 2026
Drug: SX-682; Pembrolizumab · For: Melanoma Stage III; Melanoma Stage IV
Sites: Miami, Florida; Boston, Massachusetts; Rochester, Minnesota · 6 sites in all
National Cancer Institute (NCI)NIH
NCT06149481 · 60 participants (planned) · Start Mar 26, 2024 · Primary completion Oct 31, 2027
Drug: Retifanlimab; Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform and 2 more · For: Metastatic Colorectal Cancer
Sites: Bethesda, Maryland
Syntrix Biosystems, Inc.Industry
NCT06228053 · 53 participants (planned) · Start Nov 18, 2024 · Primary completion Jun 30, 2027
Drug: SX-682; Enzalutamide · For: Metastatic Castration-resistant Prostate Cancer
Sites: Los Angeles, California; San Francisco, California; Ann Arbor, Michigan · 6 sites in all
- SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04599140 · 51 participants · Start Oct 14, 2020 · Primary completion Jul 31, 2026
Drug: CXCR1/2 Inhibitor SX-682; Nivolumab · For: Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma and 18 more
Sites: Houston, Texas
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT07814352 · 40 participants (planned) · Start Sep 4, 2026 · Primary completion Sep 2029
Drug: SX-682 · For: Leptomeningeal Disease (LMD)
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
University of WashingtonAcademic, hospital or other
NCT07322341 · 32 participants (planned) · Start Oct 6, 2026 · Primary completion Nov 1, 2030
Drug: Atezolizumab; CXCR1/2 Inhibitor SX-682 · For: Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma and 2 more
Sites: Seattle, Washington
University of WashingtonAcademic, hospital or other
NCT05570825 · 30 participants (planned) · Start Apr 6, 2023 · Primary completion Jul 1, 2027
Drug: CXCR1/2 Inhibitor SX-682; Pembrolizumab · For: Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIC Lung Cancer AJCC v8 and 1 more
Sites: Seattle, Washington
Newest research
PubMed records naming it or its code names, newest first.
- ERα-PADI4-CXCL8 Axis Drives MDSC-Mediated Immune Evasion in Anaplastic Thyroid Carcinoma.
Zhang D, Cai Y, Zhang J, et al. · Adv Sci (Weinh) 2026
- Tumor-associated neutrophils in lung adenocarcinoma: from mechanisms to therapeutic targeting.
Zhang R · Front Immunol 2026
- Antibacterial and anti-virulence activity of the repurposed agent SX-682 against Staphylococcus aureus.
Wang H, Ma J, Chen C, et al. · BMC Microbiol 2026
- DysUFMylation reprograms immunosuppressive neutrophils to potentiate anti-PD-1 therapy in hepatocellular carcinoma.
Gao X, Xu M, Han Z, et al. · Cancer Lett 2026
- CXCR2 antagonism as a promising therapeutic approach for pulmonary fibrosis therapy.
Melo EM, Resende F, Ascenção FR, et al. · Biomed Pharmacother 2026
- The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis.
Sherry C, Dadgar N, Liu Z, et al. · Curr Oncol 2025
Also in development for Metastatic Castration-resistant Prostate Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- BMS-986365Phase 31 trial
Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.